• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameBAYER ACS:180 OR ADVIA CENTAUR COMPLEX PSA ASSAYS
Classification Nameantigen(complexed),prostate specific,(cpsa)
ApplicantBAYER CORP.
PMA NumberP990055
Supplement NumberS001
Date Received03/27/2001
Decision Date12/07/2001
Product Code
NAF[ Registered Establishments with NAF ]
Advisory Committee Immunology
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications - specifications
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the addition of the assay to the bayer acs:180 and advia centaur analyzers. The device, as modified, will be marketed under the trade names bayer acs:180 or advia centaur complexed psa assay and are indicated as follows: this in vitro device is intended to quantitatively measure complexed prostate-specific antigen (cpsa) in human serum using the bayer diagnostics immuno 1, the acs:180 system, or the advia centaur system. This device is indicated for the measurement of serum complexed psa in conjunction with digital rectal exam (dre) as an aid in the detection of prostate cancer in men aged 50 years or older.
-
-